Annual Press Conference Financial year 2017

Transcription

1 Annual Press Conference 2018 Financial year 2017

2 Financial year Hubertus von Baumbach Chairman of the Board of Managing Directors 2017

3 Highly successful financial year 2017

4 Major success with human pharmaceuticals spiriva 3.19 billion USD pradaxa 1.62 billion USD jentadueto trajenta med / * 1.51 billion USD jardiance * 1.14 billion USD medicines micardis Med 1.13 billion USD ofev 1.03 billion USD *in collaboration with Eli Lilly and Company Annual Press Conference

5 Great benefit for patients

6 Great benefit for patients

7 Financial year 2017 Michael Schmelmer Member of the Board of Managing Directors responsible for Finance

8 2017 Highly successful year for Boehringer Ingelheim

9 2017 Highly successful year for Boehringer Ingelheim Net sales: 18.1 billion euros %* Operating income: 3.5 billion euros + 21% Return of sales: 19.3% +1.2 percentage points Group profit -0.2 billion euros (-2.1 billion euros) R&D expenditure: 3.1 billion euros -1.1% *currency-adjusted Annual Press Conference

10 High liquidity and equity safeguard independence

11 High liquidity and equity safeguard independence Financial funds of EUR 8.1 billion safeguard independence and financial mobility Cash flow from operating activities once again exceeds investments in tangible and intangible assets significantly 12.0 Cash flow from operating activities Cash flow from investing activities Cash flow from financing activities 8.1 Financial funds in billion euros and rounded Financial funds Annual Press Conference

12 High liquidity and equity safeguard independence Total assets: EUR 28.4 billion Sound equity structure: Equity of EUR 10.7 billion equivalent to equity ratio of 37.7% Tangible and intangible assets covered completely by equity Intangible assets Tangible assets Other assets Equity Pension provisions Other liabilities Assets Liabilities & Equity Annual Press Conference

13 Growth in all businesses

14 Growth in all businesses HP 12.6 in EUR billion AH BIO 0.9 Discontinued operations and others Sales growth of businesses (currency-adjusted): Human pharmaceuticals (HP): + 6.9% Animal Health (AH): % Biopharmaceutical contract manufacturing (BIO): % Discontinued operations and others % Annual Press Conference

15 Human pharmaceuticals: Sales performance exceeds expectations HP in EUR billion % of group net sales +6.9% (currency-adjusted) compared with the previous year Net sales of important products growth currency-adjusted spiriva EUR 2.8bn (-3.9%) pradaxa EUR 1.4bn (+5.2%) trajenta /jentadueto * EUR 1.3bn (+20.5%) jardiance * EUR 1.01bn (+135.7%) ofev EUR 0.92bn (+52.3%) *in collaboration with Eli Lilly and Company Annual Press Conference

16 Animal Health: Strong growth in net sales through transaction in EUR billion 3.9 AH 22% of group net sales % (currency-adjusted) compared with previous year Net sales of important products growth currency-adjusted nexgard frontline EUR 546m EUR 381m ingelvac circoflex EUR 302m (+7.0%) heartgard EUR 284m Annual Press Conference

17 Biopharmaceutical contract manufacturing: Increase in net sales in EUR billion 0.7 BIO 4% of group net sales +10.7% (currency-adjusted) compared with previous year Main activities: contract manufacturing for Boehringer Ingelheim and external customers One-stop-shop: from cell line development to drug product Global supply of biopharmaceutical medications for clinical studies, launch and market Annual Press Conference

18 Growth in all regions Americas 8.1 billion euros +31.0% Europe 5.7 billion euros +6.3% Asia/ Australia/Africa 4.2 billion euros +4.7% Net sales development currency-adjusted Annual Press Conference

19 USA is the most important sales market 6.9 billion euros net sales 8,000 employees USA largest market for all core businesses Around 8,000 employees at 14 facilities USD 217 million investment in biopharmaceutical production in Fremont Expansion of production capacity for animal vaccines at two facilities planned Good development of human pharmaceuticals business in an intensely changed market USA important R&D site for human pharmaceuticals and animal health Annual Press Conference

20 Germany is third-largest market 5% of total net sales 31% of global workforce 39% of global R&D expenditure 31% of total investments Annual Press Conference

21 Strong growth in emerging markets +28.1% currency-adjusted 3.4 billion euros China ~0,8 billion euros Brazil 0.4 billion euros Annual Press Conference

22 Strong double-digit growth in China Around 3,600 employees at 5 sites and in 15 offices Very dynamic market 2017: +43% net sales growth (currency-adjusted) Planned investments: 150 Million euros (over the past 20 years: investments of more than 200 million euros) Annual Press Conference

23 Further growth with Hubertus von Baumbach Chairman of the Board of Managing Directors innovative approaches

24 Improving the treatment of stroke patients Support for stroke centers in preparation for acute care under the Angels Initiative By May 2019, 1,500 centers planned in Europe alone Cooperation with national and international stroke organisations Annual Press Conference

25 Improving the treatment of stroke patients Opening of rehabilitation facility for stroke patients in Shanghai, China; a second centre is planned for Portugal by 2020 Our objective: Establishing the high standard of care comparable to that of German stroke rehabilitation in selected centres. Annual Press Conference

26 New ventures Innovative approaches in research

27 New ventures Innovative approaches in research Investment of some 2.5 billion euros in R&D for Human Pharmaceuticals every year Well-filled pipeline with 80 development projects 2017: Record year for first use by patients - 13 new active ingredients in all five therapeutic areas 65 per cent of pipeline projects have potential for therapeutic breakthrough or to be first in class Annual Press Conference

28 Animal Health: Using collective power Annual Press Conference

29 Rabies: Vaccination of animals saves lives 59,000 people die of rabies every year 95 per cent of these deaths occur in Africa and Asia Prevention through vaccination, primarily of dogs and cats In cooperation with other companies, universities and local authorities Annual Press Conference

30 Vaccinations against foot-and-mouth disease Foot-and-mouth disease is a highly infectious disease spreading quickly through infected animals with high mortality rate Joint Venture with Chinese partner for research, development and production of vaccination against foot-and-mouth disease Investment of more than 100 million euros Annual Press Conference

31 Into the future with bits and bytes Michael Schmelmer Member of the Board of Managing Directors responsible for Finance

32 Digital transformation at Boehringer Ingelheim Business strategy Digital disruption (Business units and BI X) Investment in start-ups (digital acquisitions) Transformation of the core (within business units) Business units BI X BI Digital Health Venture Fund Research & Development Medicine Patients Annual Press Conference

33 Open collaboration approaches in research Open cooperation on selected substances according to the principle: learning by sharing 20 molecules available for free use to scientists on web portal and 2 molecules on exclusive cooperation basis More than 350 enquiries for the free molecules since launch of portal Annual Press Conference

34 Digital projects for patients and physicians Important goal to improve diagnostics in rare diseases Smart stethoscope analyses lung sounds and helps in the early diagnosis of pulmonary diseases Artificial intelligence helps to evaluate computer tomographic images of the lung Our objective: Supporting patients and physicians with digital projects. Annual Press Conference

35 Digital innovation in animal health App PetPro Connect enables direct digital connection between pet owners and veterinarians Easy redemption of rebates Access to different online services provided by veterinarians Patient details of pets soon to be available on smartphone First users are testing the app in the USA Annual Press Conference

36 Summary and outlook Hubertus von Baumbach Chairman of the Board of Managing Directors

37 2017 Overview of most important facts Significant sales growth Significantly increased operating result and profitability Focus on patients Annual Press Conference

38 Outlook 2018 Slight net sales growth* planned * On comparable basis

39 The future of the pharmaceuticals business

40 Annual Press Conference 2018 Financial year 2017